Tower Research Capital (TRC)’s Kindred Biosciences, Inc. KIN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-5,575
Closed -$51K 6590
2021
Q2
$51K Buy
5,575
+2,819
+102% +$16.4K ﹤0.01% 3019
2021
Q1
$14K Sell
2,756
-7,458
-73% -$36K ﹤0.01% 4187
2020
Q4
$44K Sell
10,214
-33,423
-77% -$136K ﹤0.01% 3245
2020
Q3
$188K Buy
43,637
+35,429
+432% +$148K ﹤0.01% 2634
2020
Q2
$37K Buy
8,208
+7,587
+1,222% +$33.9K ﹤0.01% 3297
2020
Q1
$2K Buy
+621
New +$5.27K ﹤0.01% 2693
2019
Q4
Sell
-6,708
Closed -$46K 4739
2019
Q3
$46K Buy
+6,708
New +$49.2K ﹤0.01% 1859
2019
Q2
Sell
-625
Closed -$6K 4592
2019
Q1
$6K Buy
625
+389
+165% +$3.95K ﹤0.01% 3006
2018
Q4
$3K Buy
236
+174
+281% +$2.19K ﹤0.01% 3269
2018
Q3
$1K Sell
62
-9,609
-99% -$130K ﹤0.01% 3664
2018
Q2
$103K Buy
9,671
+8,552
+764% +$83.4K 0.01% 1424
2018
Q1
$10K Buy
+1,119
New +$9.82K ﹤0.01% 2480
2017
Q4
Sell
-3,266
Closed -$25K 4248
2017
Q3
$25K Buy
+3,266
New +$24.5K ﹤0.01% 2598
2017
Q2
Sell
-4,699
Closed -$33K 3727
2017
Q1
$33K Buy
4,699
+3,320
+241% +$20.8K ﹤0.01% 976
2016
Q4
$6K Buy
+1,379
New +$6.67K ﹤0.01% 2991
2016
Q3
Sell
-1,455
Closed -$5K 4782
2016
Q2
$5K Sell
1,455
-3,578
-71% -$13.2K ﹤0.01% 3438
2016
Q1
$17K Sell
5,033
-19,430
-79% -$68.6K ﹤0.01% 1489
2015
Q4
$83K Buy
24,463
+21,420
+704% +$99.4K 0.01% 355
2015
Q3
$16K Buy
3,043
+690
+29% +$4.25K ﹤0.01% 1945
2015
Q2
$16K Buy
+2,353
New +$16.7K ﹤0.01% 2311
2015
Q1
Sell
-1,024
Closed -$8K 5122
2014
Q4
$8K Buy
+1,024
New +$8.69K ﹤0.01% 2378
2014
Q3
Sell
-100
Closed -$1.35K 5060
2014
Q2
$2K Sell
100
-402
-80% -$6.83K ﹤0.01% 3502
2014
Q1
$9K Sell
502
-4,416
-90% -$84.2K ﹤0.01% 2744
2013
Q4
$55K Buy
+4,918
New +$58.6K 0.01% 1304

Other funds holding KIN

Tower Research Capital (TRC)'s KIN Position: Q3 2021 in Review

Tower Research Capital (TRC) sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 5,575 shares — an estimated $51K sold.

Tower Research Capital (TRC) first reported a position in KIN in Q4 2013 and held it in 24 quarters. The position peaked at $188K in Q3 2020. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.

  • Tower Research Capital (TRC) reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 5,575 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $51K.
  • Tower Research Capital (TRC) first reported a position in Kindred Biosciences, Inc. in Q4 2013 and held it in 24 quarters.
  • Tower Research Capital (TRC)'s Kindred Biosciences, Inc. position peaked at $188K in Q3 2020.
  • 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2021, filed 15 Nov 2021.